Kane Sunanda V, Bjorkman David J
University of Chicago, Chicago, Illinois, USA.
Rev Gastroenterol Disord. 2003 Fall;3(4):210-8.
The authors set out to critically review the current data on the efficacy of oral 5-aminosalicylic acid (5-ASA) agents for active ulcerative colitis (UC). Thirty-one studies were identified; 19 met entry criteria. Three trials with mesalamine showed statistical significance versus placebo; those with olsalazine or balsalazide did not. No agent was statistically different from sulfasalazine. In 2 of 3 trials of balsalazide versus mesalamine, results for defined primary and secondary endpoints failed to demonstrate statistically significant differences. Studies suggest that mesalamine is superior to placebo for treating active UC. Five-ASA products appear to be as effective as sulfasalazine, but available data do not suggest a difference in efficacy between any of the 5-ASA preparations.
作者们着手对目前关于口服5-氨基水杨酸（5-ASA）制剂治疗活动性溃疡性结肠炎（UC）疗效的数据进行批判性综述。共识别出31项研究；19项符合纳入标准。三项美沙拉嗪试验显示与安慰剂相比具有统计学意义；而奥沙拉嗪或巴柳氮试验则未显示出统计学意义。没有一种制剂与柳氮磺胺吡啶在统计学上有差异。在巴柳氮与美沙拉嗪的三项试验中的两项中，明确的主要和次要终点结果未能显示出统计学上的显著差异。研究表明，美沙拉嗪治疗活动性UC优于安慰剂。5-ASA产品似乎与柳氮磺胺吡啶一样有效，但现有数据并未表明任何一种5-ASA制剂在疗效上存在差异。
